BR112018007161A2 - pirazolo[3,4-b]piridin-6-carboxamidas n-sulfoniladas e métodos de uso - Google Patents

pirazolo[3,4-b]piridin-6-carboxamidas n-sulfoniladas e métodos de uso

Info

Publication number
BR112018007161A2
BR112018007161A2 BR112018007161-7A BR112018007161A BR112018007161A2 BR 112018007161 A2 BR112018007161 A2 BR 112018007161A2 BR 112018007161 A BR112018007161 A BR 112018007161A BR 112018007161 A2 BR112018007161 A2 BR 112018007161A2
Authority
BR
Brazil
Prior art keywords
sulfonylated
carboxamides
pyrazolo
pyridin
methods
Prior art date
Application number
BR112018007161-7A
Other languages
English (en)
Other versions
BR112018007161B1 (pt
Inventor
Akkari Rhalid
Jonathan Alvey Luke
Marie Bock Xavier
S. Brown Brian
Isabelle Roger Claes Pieter
D Cowart Marlon
De Lemos Elsa
Desroy Nicolas
Duthion Béranger
A. Gfesser Gregory
Luc Marie Gosmini Romain
Gaëtan Housseman Christopher
Karel Jansen Koen
Ji Jianguo
R. Kym Philip
Mammoliti Oscar
Lefrancois Jean-Michel
Merayo Merayo Nuria
Jeanne Marie Menet Christel
Marie Elise Palisse Adeline
John Robert Newsome Gregory
Rafaël Pizzonero Mathieu
V. Patel Sachin
C. Swift Elizabeth
Shrestha Anurupa
Wang Xueqing
Emiel Van Der Plas Steven
De Blieck Ann
Original Assignee
AbbVie S.à.r.l.
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie S.à.r.l., Galapagos Nv filed Critical AbbVie S.à.r.l.
Publication of BR112018007161A2 publication Critical patent/BR112018007161A2/pt
Publication of BR112018007161B1 publication Critical patent/BR112018007161B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

a presente invenção proporciona compostos de fórmula (i) (i) caracterizado pelo fato de que r1, r2, r3, r4, r5, e r6 têm qualquer um dos valores definidos no relatório descritivo, e os seus sais farmaceuticamente aceitáveis, que são úteis como agentes no tratamento de doenças e condições me-diadas e moduladas por cftr, incluindo fibrose cística, síndrome de sjögren, insu-ficiência pancreática, doença pulmonar obstrutiva crônica, e doença obstrutiva crô-nica das vias aéreas. são também proporcionadas composições farmacêuticas compostas por um ou mais compostos de fórmula (i).
BR112018007161-7A 2015-10-09 2016-10-07 COMPOSTOS PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDA N-SULFONILADA, COMPOSIÇÃO FARMACÊUTICA CONTENDO OS DITOS COMPOSTOS E USOS DOS MESMOS PARA TRATAR FIBROSE CÍSTICA BR112018007161B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562239647P 2015-10-09 2015-10-09
US62/239,647 2015-10-09
US201662309794P 2016-03-17 2016-03-17
US62/309,794 2016-03-17
PCT/IB2016/056029 WO2017060874A1 (en) 2015-10-09 2016-10-07 N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use

Publications (2)

Publication Number Publication Date
BR112018007161A2 true BR112018007161A2 (pt) 2018-10-30
BR112018007161B1 BR112018007161B1 (pt) 2024-01-16

Family

ID=57209654

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018007161-7A BR112018007161B1 (pt) 2015-10-09 2016-10-07 COMPOSTOS PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDA N-SULFONILADA, COMPOSIÇÃO FARMACÊUTICA CONTENDO OS DITOS COMPOSTOS E USOS DOS MESMOS PARA TRATAR FIBROSE CÍSTICA

Country Status (32)

Country Link
US (4) US9890158B2 (pt)
EP (1) EP3359541B1 (pt)
JP (1) JP6779992B2 (pt)
KR (1) KR20180083323A (pt)
CN (1) CN108513574B (pt)
AU (1) AU2016333856C1 (pt)
BR (1) BR112018007161B1 (pt)
CA (1) CA3001096A1 (pt)
CL (1) CL2018000911A1 (pt)
CO (1) CO2018003716A2 (pt)
CR (1) CR20180215A (pt)
CY (1) CY1123545T1 (pt)
DK (1) DK3359541T3 (pt)
EC (1) ECSP18032223A (pt)
ES (1) ES2829636T3 (pt)
HR (1) HRP20201618T1 (pt)
HU (1) HUE051067T2 (pt)
IL (1) IL258553A (pt)
LT (1) LT3359541T (pt)
MX (1) MX2018004359A (pt)
NZ (1) NZ741223A (pt)
PE (1) PE20181348A1 (pt)
PH (1) PH12018500765A1 (pt)
PL (1) PL3359541T3 (pt)
PT (1) PT3359541T (pt)
RU (1) RU2724345C2 (pt)
SG (1) SG11201802932VA (pt)
SI (1) SI3359541T1 (pt)
TW (1) TWI720032B (pt)
UY (1) UY36943A (pt)
WO (1) WO2017060874A1 (pt)
ZA (1) ZA201802976B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018007161B1 (pt) 2015-10-09 2024-01-16 Galapagos Nv COMPOSTOS PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDA N-SULFONILADA, COMPOSIÇÃO FARMACÊUTICA CONTENDO OS DITOS COMPOSTOS E USOS DOS MESMOS PARA TRATAR FIBROSE CÍSTICA
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
EP3558982A1 (en) 2016-12-20 2019-10-30 AbbVie S.À.R.L. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
GB201905711D0 (en) 2019-04-24 2019-06-05 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
US11345691B2 (en) 2019-06-03 2022-05-31 AbbVie Global Enterprises Ltd. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
CN114761383A (zh) * 2019-06-12 2022-07-15 诺瑟拉有限公司 磺酰胺衍生物及其用途
US11236067B2 (en) 2019-07-12 2022-02-01 Orphomed, Inc. Compound for treating cystic fibrosis
KR20230008763A (ko) 2020-05-08 2023-01-16 할리아 테라퓨틱스, 인코포레이티드 Nek7 키나제의 저해제
TW202208368A (zh) 2020-06-08 2022-03-01 美商哈利亞製藥公司 Nek7激酶抑制劑
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
KR20230052954A (ko) 2020-08-20 2023-04-20 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 점액 과다분비를 특징으로 하는 호흡기 질환의 치료 방법
WO2022150174A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2022150173A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
AU2023215372A1 (en) 2022-02-03 2024-08-22 Vertex Pharmaceuticals Incorporated Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
TW202333699A (zh) 2022-02-03 2023-09-01 美商維泰克斯製藥公司 囊腫纖維化之治療方法
WO2023154291A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2023224931A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN115806532A (zh) * 2022-08-31 2023-03-17 大连百傲化学股份有限公司 一种mit中杂质的制备方法
US20240158394A1 (en) 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors
CN115960100B (zh) * 2022-12-28 2023-08-18 北京康立生医药技术开发有限公司 一种治疗胃肠道间质瘤药物皮咪特昔布的合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833598A (en) * 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
AU2005223351A1 (en) * 2004-03-16 2005-09-29 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor
WO2005120497A2 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CN107501099B (zh) 2004-06-24 2021-03-19 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
JP5092402B2 (ja) * 2004-07-05 2012-12-05 アステラス製薬株式会社 ピラゾロピリジン誘導体
US8362031B2 (en) * 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
HUE025553T2 (en) 2007-05-25 2016-02-29 Vertex Pharma CFTR modulators
AU2008323694A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
CA2709301C (en) 2007-12-13 2016-05-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
JP5645835B2 (ja) 2008-10-23 2014-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｎ−（４−（７−アザビシクロ［２．２．１］ヘプタン−７−イル）−２−（トリフルオロメチル）フェニル）−４−オキソ−５−（トリフルオロメチル）−１，４−ジヒドロキノリン−３−カルボキサミドの固体形態
JP5699090B2 (ja) 2008-12-30 2015-04-08 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子のモジュレーター
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2826771B1 (en) * 2010-09-14 2018-12-12 Instytut Biochemii I Biofizyki Polskiej Akademii Nauk Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction
RU2599144C2 (ru) 2010-10-08 2016-10-10 Нивалис Терапьютикс,Инк. Новые замещенные хинолиновые соединения как ингибиторы s-нитрозоглутатион-редуктазы
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
BR112014006535A2 (pt) 2011-09-20 2017-03-28 Univ North Carolina Chapel Hill regulação dos canais de sódio através das proteínas plunc
CN104024251B (zh) * 2011-10-31 2017-08-11 克赛农制药股份有限公司 苯磺酰胺化合物及其作为治疗剂的用途
AU2013348018A1 (en) * 2012-11-20 2015-06-04 Discoverybiomed, Inc. Small molecule CFTR correctors
LU92578B1 (fr) 2013-05-07 2014-12-15 Galapagos Nv Nouveaux composés et compostions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose
AU2014304562B8 (en) 2013-08-08 2018-07-05 Galapagos Nv Thieno[2,3-c]pyrans as CFTR modulators
RU2016135637A (ru) * 2014-02-06 2018-03-12 Эббви Инк. 6-гетероарилокси- и 6-арилоксихинолин-2-карбоксамиды и их применение
CA2942387A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr actvity
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
LT3212189T (lt) 2014-10-31 2020-11-25 Abbvie Overseas S.A R.L. Pakeisti chromanai ir naudojimo būdas
AU2015339196A1 (en) 2014-10-31 2017-05-11 Abbvie S.A.R.L. Substituted tetrahydropyrans and method of use
JP2018529707A (ja) * 2015-10-09 2018-10-11 アッヴィ・エス・ア・エール・エル 嚢胞性線維症の処置のための新規な化合物
BR112018007161B1 (pt) * 2015-10-09 2024-01-16 Galapagos Nv COMPOSTOS PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDA N-SULFONILADA, COMPOSIÇÃO FARMACÊUTICA CONTENDO OS DITOS COMPOSTOS E USOS DOS MESMOS PARA TRATAR FIBROSE CÍSTICA

Also Published As

Publication number Publication date
RU2018115722A (ru) 2019-11-12
US20190202823A1 (en) 2019-07-04
ZA201802976B (en) 2019-07-31
AU2016333856A1 (en) 2018-04-26
CN108513574B (zh) 2021-01-05
US10259810B2 (en) 2019-04-16
NZ741223A (en) 2023-03-31
LT3359541T (lt) 2020-11-25
PE20181348A1 (es) 2018-08-22
EP3359541A1 (en) 2018-08-15
KR20180083323A (ko) 2018-07-20
SI3359541T1 (sl) 2021-01-29
ES2829636T3 (es) 2021-06-01
JP6779992B2 (ja) 2020-11-04
IL258553A (en) 2018-05-31
CR20180215A (es) 2018-06-05
US20180105522A1 (en) 2018-04-19
TWI720032B (zh) 2021-03-01
HUE051067T2 (hu) 2021-01-28
DK3359541T3 (da) 2020-11-09
CO2018003716A2 (es) 2018-07-19
PH12018500765B1 (en) 2018-10-01
PL3359541T3 (pl) 2021-01-11
JP2018529743A (ja) 2018-10-11
CN108513574A (zh) 2018-09-07
PH12018500765A1 (en) 2018-10-01
BR112018007161B1 (pt) 2024-01-16
SG11201802932VA (en) 2018-05-30
RU2018115722A3 (pt) 2020-02-18
TW201722948A (zh) 2017-07-01
WO2017060874A1 (en) 2017-04-13
UY36943A (es) 2017-05-31
HRP20201618T1 (hr) 2020-12-25
AU2016333856B2 (en) 2021-05-20
MX2018004359A (es) 2018-05-01
US20170101405A1 (en) 2017-04-13
US10647717B2 (en) 2020-05-12
PT3359541T (pt) 2020-11-11
CL2018000911A1 (es) 2018-08-24
US9890158B2 (en) 2018-02-13
EP3359541B1 (en) 2020-08-05
RU2724345C2 (ru) 2020-06-23
CY1123545T1 (el) 2022-03-24
US20190330207A1 (en) 2019-10-31
ECSP18032223A (es) 2018-05-31
AU2016333856C1 (en) 2021-12-09
CA3001096A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
BR112018007161A2 (pt) pirazolo[3,4-b]piridin-6-carboxamidas n-sulfoniladas e métodos de uso
BR112018007145A2 (pt) ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso
BR112018072047A2 (pt) moduladores da proteína reguladora de condutância transmembranar de fibrose cística
PH12018500088A1 (en) Substituted tricyclics and method of use
CY1119705T1 (el) Νεα παραγωγα αμινοπυριμιδινης
AU2022201816A8 (en) Pyrrolopyrimidines as CFTR potentiators
ECSP17033565A (es) Cromanos sustituidos y métodos para su uso
AU2018256602A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
BR112017007662A2 (pt) composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
BR112017024933A8 (pt) Alvocidib produce com a bioavailabilidade aumentada
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
EA201650029A1 (ru) Пиразолопиридины и пиразолопиримидины
EA201690284A1 (ru) Композиции и терапевтические способы для ускоренного регресса бляшки
BR112015023356A2 (pt) inibidores de quinase pirrol[2,3-b]piridina cdk9
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
BR112015013414A2 (pt) derivados de naftiridona e seu uso no tratamento, melhora ou prevenção de uma doença viral
EA201990834A1 (ru) Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний
MX2017008931A (es) Formulaciones farmaceuticas de xantina o derivados de xantina.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: GALAPAGOS NV (BE) ; ABBVIE OVERSEAS S.A.R.L. (LU)

B25A Requested transfer of rights approved

Owner name: GALAPAGOS NV (BE) ; ABBVIE OVERSEAS S.A.R.L. (LU) ; ABBVIE GLOBAL LIMITED (BM)

B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: GALAPAGOS NV (BE) ; ABBVIE GLOBAL LIMITED (BM)

Free format text: RETIFICADO O DESPACHO 25.1 PUBLICADO NA RPI 2755 DE 24/10/2023 SOB O ITEM (71).

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: GALAPAGOS NV (BE) ; ABBVIE GLOBAL ENTERPRISES LTD. (BM)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/10/2016, OBSERVADAS AS CONDICOES LEGAIS